|
|
|
|
Vol. 57, Issue 1, 125-134, January 2000
Departments of Receptor Biochemistry (G.C., C.W., K.Q., C.K.J., T.K.) and of Molecular Sciences (J.W., S.A., W.-J.C.), Glaxo Wellcome Research and Development, Research Triangle Park, North Carolina
| |
Abstract |
|---|
|
|
|---|
This article describes the behavior of transiently transfected human receptors into melanophores and the potential use of constitutive receptor activity to screen for new drug entities. Specifically, transient transfection of melanophores with different concentrations of receptor cDNA presumably leads to increased levels of receptor expression. This leads to an increased response to agonists (both maxima and potency) and, in some cases, an agonist-independent constitutive receptor activity. Transfections with increasing concentrations of the Gs protein-coupled human calcitonin receptor type 2 (hCTR2) cDNA produced sufficient levels of constitutively activated receptor to cause elevated basal cellular responses. This was observed as a decrease in the transmittance of light through melanophores (consistent with Gs protein activation) and increased response to human calcitonin. The receptor-mediated nature of this response was confirmed by its reversal with the hCTR2 peptide inverse agonist AC512. A collection of ligands for hCTR2 either increased or decreased constitutive hCTR2 activity, suggesting that the constitutive system was a sensitive discriminator of positive and negative ligand efficacy. Similar results were obtained with Gi-protein-coupled receptors. Transient transfection of NPY1, NPY2, NPY4, CXCR4, and CCR5 cDNA produced increased light transmittance through melanophores (consistent with Gi-protein activation). NPY1 cDNA produced little constitutive response on transfection, whereas maximal levels of constitutive activity ranging from 30 to 45% were observed for the other Gi-protein-coupled receptors. Responses to agonists for these receptors increased (both maxima and potency) with increasing cDNA transfection. The receptor/Gi-protein nature of both the constitutive and agonist-mediated responses was confirmed by elimination with pertussis toxin pretreatment. These data are discussed in terms of the theoretical aspects of constitutive receptor activity and the applicability of this approach for the general screening of G protein-coupled orphan receptors.
| |
Introduction |
|---|
|
|
|---|
High-throughput screening with combinatorial chemical libraries is an effective method of discovery of new ligands that interact with receptor targets. The interference of receptor signals mediated by the interaction of the receptor with known ligands is the common method of detection of new entities. In the case of orphan receptors, for which there are still no known ligands, this system is capable only of discovering excitatory (agonist) ligands that cause receptor activation and thus a measurable signal.
G protein-coupled receptors (GPCRs) can spontaneously form active
states that subsequently can activate G proteins and thus produce a
measurable pharmacologic response (Costa and Herz, 1989
; Samama et al.,
1993
). Unless ligands have identical affinities for the different
activation states of seven transmembrane receptors present in
constitutive receptor systems, their binding will redistribute the
species, and this will be detected as either an increase or a decrease
in the constitutive receptor activity (see predictions of ternary
complex models describing this effect in Appendix I). There
are data to show that a measurable constitutive GPCR activity can be
obtained by receptor overexpression in recombinant systems (Appendix II; Kenakin, 1996
). Therefore, one approach to the
screening of GPCRs is to overexpress the receptor to the point of
observing constitutive activity and then allowing ligands with affinity
to redistribute the receptor species. The following are requirements
for such assays: 1) the receptor must have some proclivity to
spontaneously form an active state, 2) there must be suitable G
proteins available in the cell to interact with the active state, and
3) there must be a means to monitor the amount of activated G protein
(Kenakin, 1997
).
This article describes the study of constitutive receptor activity in
Xenopus laevis melanophores, cells that fulfill the second
and third prerequisites of the assay. Specifically, these cells contain
a wide range of G
proteins (Jayawickreme et al., 1994
);
therefore, the functional expression of numerous foreign GPCRs can be
facilitated (Potenza et al., 1992
, 1994
; Karne et al., 1993
; Graminski
et al., 1993
; McClintock et al., 1993
; Graminski and Lerner, 1994
;
Jayawickreme et al., 1994a
,b
; Lerner, 1994
). This system can be
monitored in real time by the dispersion and aggregation of melanin.
Melanosome dispersion can be affected via activation of adenylyl
cyclase (Potenza et al., 1992
; McClintock et al., 1993
) or
phospholipase C (Graminski et al., 1993
), whereas melanosome
aggregation results from the inhibition of adenylyl cyclase (Potenza et
al., 1992
; McClintock et al., 1993
). Because both states (dispersion or
aggregation) of intracellular melanosome distribution are easily
detectable, GPCRs can be studied by monitoring ligand-mediated
melanosome translocation by either measuring the change in light
transmittance through the cells or by imaging the cell response
(Potenza et al., 1992
, 1994
; Karne et al., 1993
; McClintock et al.,
1993
; Graminski et al., 1993
; Graminski and Lerner, 1994
; Jayawickreme
et al., 1994a
,b
; Lerner, 1994
).
| |
Experimental Procedures |
|---|
|
|
|---|
Materials. Leibovitz (L-15) medium came from Sigma Chemical Co. (St. Louis, MO), BSA from Boehringer Mannheim (Indianapolis, IN), and pertussis toxin (PTX) from Calbiochem (516560; La Jolla, CA).
Construction of Expression Vectors.
The full-length cDNA for
human calcitonin receptor type 2 (hCTR2) (Chen et al., 1997
), NPY1,
NPY2, NPY4 (Matthews et al., 1997
), CX chemokine receptor type 4 (CXCR4), and chemokine C receptor 5 (CCR5) (Chen et al., 1998
) were
amplified by a reverse-transcriptase polymerase chain reaction strategy
as described. DNA fragments containing coding sequences were isolated
and subcloned into the melanophore expression vector pJG3.6 (Graminski
et al., 1993
). Plasmid DNA used for melanophore transfections was
prepared by a modification of the triton-lysozyme method and double
banded in CsCl/ethidium bromide equilibrium gradients as described
(Davis et al., 1994
).
Functional Bioassay.
Melanophores were maintained in cell
cultures as previously described (Jayawickreme et al., 1994a
,b
).
Transient expression of GPCR plasmid DNA in melanophores was achieved
after electroporation (Graminski et al., 1993
; Jayawickreme et al.,
1994
). After electroporation, cells were seeded into flat-bottom
96-well tissue culture plates (Falcon Labware, Oxnard, CA) to a density
of 20,000 cells/well in conditioned fibroblast medium (CFM) and
incubated at 27°C for 24 to 48 h. Nontransfected cells did not
respond to the agonists used in this study.
Tf/Ti).
In the studies with PTX, the transfected cells were incubated overnight
(16-18 h) in CFM with 1 µg/ml of PTX. Just before the assay, the
media was removed and replaced with 0.7× L-15/0.1% BSA containing
various reagents and/or drugs.
| |
Results |
|---|
|
|
|---|
Gs Protein-Coupled Receptor (hCTR2).
Transient
transfection of melanophores with cDNA for hCTR2 resulted in a
cDNA-dependent decreased light transmittance and the acquisition of
responses to human calcitonin (hCAL). Figure 1I shows the effect of transfection of
melanophores with 32 µg of cDNA for hCTR2. Also shown are the effects
of increasing concentrations of the inverse agonist AC512. The
reduction in the melanin dispersion by AC512 indicates that it was
caused by constitutive activation of Gs protein by the
transiently expressed receptor.
|
|
|
|
|
|
|
Gi Protein-Coupled Receptors.
Corresponding data
were collected for Gi-coupled receptors. Note that
activation of Gi protein causes increased light
transmittance, which, in turn, produces more negative values for
1
(Tf/Ti). Thus, unlike the
dose-response curves for activation of Gs protein, positive
agonism produces more negative values, and inverse agonism produces
increases in 1
(Tf/Ti)
values. Figure 7A shows the effects of
transient transfection with a range of concentrations of cDNA for human
CXCR4. As can be seen from this figure, increasing levels of cDNA
produces increased basal response and a corresponding increase in the
maximal response to a natural agonist for this receptor (SDF-1
). As
with hCTR2, the location parameters of the dose-response curves to
SDF-1
shift to the left with increasing receptor transfection level.
Figure 7B shows the effects of various levels of transfection on the
maximal response to SDF-1
and the basal activity. As with hCTR2, the
maximal constitutive activity is below that produced by the agonist.
|
.
|
, and decreasing EC50 for
MIP-1
responses. Figure 9B shows that, as for CXCR4, essentially the
lowest concentration of cDNA that causes receptor expression also shows
constitutive activity; i.e., there is no threshold expression level for
constitutive receptor activity. Both the constitutive and
agonist-induced responses after receptor expression were prevented by
pretreatment of cells with PTX.
|
|
|
|
| |
Discussion |
|---|
|
|
|---|
The discovery of constitutive GPCR activity presented a
theoretical approach to the identification of ligands for orphan
receptors. The basic premise for this idea is that different tertiary
conformations of the receptor protein will display different binding
domains for ligands. Unless the affinities of the ligands for these
different domains were identical, they would bind to each conformation
according to mass action kinetics (the concentration of ligand and the
respective equilibrium dissociation constants for the ligand-receptor
conformation complex). The differential binding to these conformations
necessarily would change their relative abundance (see Appendix
I), and this redistribution necessarily would alter the
concentration of the signaling species, namely,
RaG (see Fig.
13). The magnitude of the observed
response depends on the amount of RaG species formed and the sensitivity of the stimulus-response machinery of the
cell. Theoretically, any sensitive functional assay (e.g., reporters,
yeast) could be used for constitutive screening. Melanophores were
chosen in this study because of the high sensitivity of the stimulus-response mechanisms for Gs, Gi, and
Gq in this cell line. Many GPCRs have been successfully
transiently expressed in these cells with concomitant observation of
Gi, Gs, and Gq activation. Finally,
note that responses in melanophores can be viewed in real time (see
Fig. 2), thereby allowing the direct observation of steady states.
|
The propensity of a given GPCR to form the active state is an inherent
property of the receptor. In terms of the ternary complex model, this
is defined by the allosteric constant (L in Fig. 13) as
[Ra]/[Ri]. Although there are
instances where this can be altered biochemically (i.e., removal of
Na+; Costa and Herz, 1989
; Tian et al., 1994
) for some
receptors, the usual method of creating a constitutively active
receptor system is to manipulate the stoichiometry of receptors and G
proteins. For example, constitutive activity has been observed with
increasing receptor expression (i.e.,
2-adrenoceptors;
Samama et al., 1993
; thyroid-stimulating hormone receptors; Van Sande
et al., 1995
) and enrichment of G proteins (Senogles et al., 1990
). The
rationale for this approach is that, because the allosteric constant
controls the fraction of receptors in the activated state, a critical
concentration of active receptors, for the creation of observable
response, can be obtained by simply increasing the number of receptors
expressed. The data obtained with the receptors in this study are
consistent with this idea but also highlight the uniqueness of
different types of receptors. Relatively high levels of constitutive
activity were attained with the Gi protein-coupled
receptors NPY2, NPY4, CXCR4, and CCR5; however, NPY1 was uniquely
quiescent and produced little observed constitutive activity at cDNA
levels that clearly allowed cell surface receptor expression (as
evidenced by the responses to the agonist PYY).
Note that the application of the models to the observed data tacitly assumes that exposing the cells to increasing levels of receptor cDNA leads to increasing receptor expression. However, this assumption is not limiting to the use of constitutive activity for screening purposes, because the transient transfection is titrated to a given level of response regardless of the actual receptor density present on the membrane.
If the host cell sensitivity to active-state receptor is low, then, conceivably, high receptor transfection levels would be required before sufficiently high levels of active receptor could spontaneously be generated to produce visible response. In contrast, there would be much less limitation on agonist-induced response, because saturating concentrations of full agonist would lead to conversion of all existing receptors into the active state. Under these circumstances, a threshold phenomenon would be predicted in which receptor transfection would take place (and response to agonist would be observed), but no constitutive receptor activity would be observed until considerably greater levels of receptor expression. Surprisingly, whereas a slight threshold effect was observed in these studies for NPY2 and NPY4, essentially constitutive receptor activity was observed with almost all levels of receptor expression. This suggests that melanophores have high responsiveness characteristic to GPCR activity, an idea supported by the high sensitivity of agonists in this system.
Another interesting outcome of this study was the results of the limited test of the notion that most ligands with affinity for any given GPCR will have differential affinity for the various states of the receptor and thus show a detectable response in the constitutively active receptor system. As shown in Fig. 6, ligands known to bind to hCTR2 either produced positive agonism or negative agonism; there were no "neutral" antagonists in this collection of ligands. Although this clearly is a limited sample, it is interesting that the data were consistent with the thermodynamic prediction.
Two versions of the ternary complex model predict different degrees of
maximal constitutive receptor activity from GPCR systems (Appendix II). The extended ternary complex model predicts that the same maximal response that is produced by an agonist should be
observed constitutively with high receptor expression levels (if the
amount of receptor is not limiting). A different prediction is
consistent with the cubic ternary complex model, which allows for the
inactive state of the receptor to interact with G proteins.
Interestingly, antagonist-induced receptor/G protein interactions
leading to ternary complexes that do not signal
(ARiG complex in Fig. 13) have been reported for
MOR-1 (Brown and Pasternak, 1998
). Also, nonsignaling ternary complexes
with the inverse agonist SR 144528 have been reported for cannabinoid receptors (Bouaboula et al., 1997
, 1999
). If such nonsignaling complexes are formed, then this model predicts that a limit can be
reached where the maximal constitutive response will be lower than the
agonist-induced maximal response according to system parameters
describing the ability of the receptor to form the active state
(allosteric factor L) and the differential affinity of the
activated receptor (over the inactive state) for G proteins (
in
Fig. 13). As seen in Figures 5, 7, and 9 through 12, the maximal constitutive activity observed was substantially lower than the agonist-induced maximal response. Whereas this ostensibly indicates that the cubic model better describes GPCR systems, note that there is
no way of knowing whether the amount of receptor transfected into the
melanophores did not limit the maximal interaction between receptor and
G protein. Therefore, the submaximal constitutive receptor activity
does not furnish definitive evidence for nonsignaling receptor/G
protein complexes.
The data presented with these receptors indicate that a constitutive
GPCR assay is a viable alternative for screening orphan receptors. The
advantage of such an approach lies in the expanded window of detection.
Not only will agonists be found but also inverse agonists. This option
is not available in nonconstitutively active screens in which only
positive agonists will be detected. Another advantage of constitutive
screens is the fact that they can be more sensitive to agonists than
quiescent assays (Appendix III and Fig. 4). Theoretically,
this also applies to inverse agonists, although for these ligands
(where
and
< 1), the enhancing effects of constitutive
activity will be severely dampened so as to become nearly
insignificant. Interestingly, whereas an increased sensitivity to the
positive agonist human calcitonin was observed in this study (Fig. 4A),
little change in potency for the inverse agonist AC66 was seen (Fig.
4B), agreeing with this prediction.
The possible disadvantage of this assay is the added variability of screening with transient transfections. The level of constitutive activity varies with the efficiency of receptor transfection, which, in turn, affects the sensitivity of the assay to positive and negative agonism (see Appendix III). It is difficult to predict, in general terms, whether this variability is too high a cost for constitutive screening. The key probably lies in the nature of the receptor, the efficiency of receptor expression, the magnitude of the allosteric constant L, and the host cell system (i.e., stoichiometry of the G proteins available for interaction with the active-state receptor). In general, the main drawback to constitutive systems would be the possibility of decreasing the positive scale for potential agonism (i.e., the constitutive activity approaches the endogenous agonist maximal response). With appropriate controls (i.e., the measurement of the maximal detectable levels of increased Gs or Gi/Gq activation with standard agonists), the control of constitutive receptor activity below these levels would be sufficient to ensure the possibility of detection of positive agonists.
These data are consistent with the idea that constitutive GPCR systems can be made sufficiently sensitive and stable to be used in screening for ligands. The fact that all but one of the receptors we tested provided substantial constitutive activity suggests that this approach would be especially useful for the screening of orphan receptors.
| |
Appendices |
|---|
|
|
|---|
Certain predictions can be made from the extended ternary complex
(ETC) model as presented by Samama et al. (1993
; Fig. 13A)
and the cubic ternary complex (CTC) model (Weiss et al.,
1996a
,b
; Fig. 13B) about the relationship among receptor density,
constitutive response, sensitivity to ligands, and the ability to
discern receptor conformations. Note that the models described below
are binding models that do not take into account GTP activation of
the G protein, and, as such, they may not adequately describe
functional systems.
| |
Appendix: Enrichment of Receptor Conformation by Conformational Selection |
|---|
|
|
|---|
Differential affinities for different receptor conformations (as
found in constitutively active receptor systems) leads to enrichment of
the species for which the ligand has the highest affinity. This can be
illustrated with a system containing two receptor conformations
R and R* that coexist in the system according to
an allosteric constant denoted L'
|
(1) |
Ka. The factor
denotes the differential
affinity of the agonist for R*, i.e., if
= 10, then
the agonist has a 10-fold greater affinity for the R* form.
The complete scheme with ligand involved is then
|
> 1) enrich the R* species?
This can be calculated by examining the amount of R* species
(both as R* and AR*) present in the system in
the absence of ligand and in the presence of ligand. The
equilibrium expression for [R*] + [AR*])/(Rtot], where [Rtot] is the total receptor concentration
given by the conservation equation [Rtot] = [R] + [AR] + [R*] + [AR*]) is
|
(2) |
is the
differential affinity of the ligand for the R* state. It can
be seen that, in the absence of agonist ([A] = 0),
0 = L/(1 + L) and in the presence of a
maximal concentration of ligand (saturating the receptors; ([A]
) 
= [
(1 + L)]/(1 +
L).
Therefore, the effect of a ligand on enriching the R* state
is given by the ratio 
/
0; when this
ratio is >1, then the presence of the ligand enriches the
R* state. This ratio is given by
|
(3) |
= 1), then 
/
0 will equal unity, and no
enrichment of the R* will result from maximal ligand
binding. However, if
> 1, then the presence of the
conformationally selective ligand will cause the ratio

/
0 to be >1. For example, if the
affinity of the ligand is 10-fold greater for the R* state,
then in a system where 10% of the receptors are spontaneously in this
state (L = 0.1), the saturation of the receptors
with this agonist will increase the amount of R* by a factor
of 1.8 (10-18%), and positive agonism (if R* mediates constitutive response) will result. Similarly, if
< 1, then a
ligand will diminish the amount of R*, and inverse agonism
will result.
| |
Appendix: Dependence of Basal Constitutive Receptor Activity on Receptor Density |
|---|
|
|
|---|
ETC Model.
The equilibrium equations for the G protein species
are
|
(4) |
|
(5) |
|
(6) |
|
(7) |
|
(8) |
|
(9) |
. This equals unity; thus, eq. 9 also yields the expression for constitutive activity as a function of receptor density expressed as a fraction of the maximal response to a full agonist. It can be seen
from eq. 9 that, if receptor density is not limiting (i.e., as
[Ri]
), then the maximal constitutive
activity predicted by the ETC model is unity (i.e., the
maximal response produced by a full agonist).
CTC Model.
The equilibrium equations for the G protein species
are
|
(11) |
|
(12) |
|
(13) |
|
(14) |
|
(15) |
|
(16) |
|
(17) |
|
(18) |
|
(19) |
|
(20) |
), then the constitutive activity,
as a function of the maximal agonist-stimulated activity, will reach an
asymptotic value of
|
(21) |
|
(22) |

1), then, 1/
0, and the expression reduces to
|
(23) |
| |
Appendix: Effect of Constitutive Activity on Observed Potency of Agonists |
|---|
|
|
|---|
ETC Model.
From the equation describing response (eq. 8), the
observed affinity of an agonist is given by
|
(3) |
|
(24) |
,
< 1), if observed at all.
CTC Model.
From the equation describing response (eq. 17), the
observed affinity of an agonist is given by
|
(25) |
|
(26) |
| |
Acknowledgment |
|---|
We thank Donna McGhee for expert preparation of this manuscript.
| |
Footnotes |
|---|
Received August 23, 1999; Accepted October 6, 1999
Send reprint requests to: Terry Kenakin, Ph.D., Department of Receptor Biochemistry, Glaxo Wellcome Research and Development, 5 Moore Drive, Research Triangle Park, NC 27709. E-mail: TPK1348{at}glaxo.com
| |
Abbreviations |
|---|
hCTR2, human calcitonin receptor type 2; GPCR, G protein-coupled receptor; PTX, pertussis toxin; CFM, conditioned fibroblast medium; hCAL, human calcitonin.
| |
References |
|---|
|
|
|---|
-opioid receptors coupled to GTP-binding proteins.
Proc Natl Acad Sci USA
86:
7321-7325
-melanocyte-stimulating hormone antagonists.
J Biol Chem
269:
29846-29854
2-adrenergic receptor: Extending the ternary complex model.
J Biol Chem
268:
4625-4636
2-adrenergic receptor activation of G proteins: Evidence for a precoupled receptor/G protein state.
Mol Pharmacol
45:
524-531[Abstract].This article has been cited by other articles:
![]() |
C. M. Allan, P. Lim, M. Robson, J. Spaliviero, and D. J. Handelsman Transgenic mutant D567G but not wild-type human FSH receptor overexpression provides FSH-independent and promiscuous glycoprotein hormone Sertoli cell signaling Am J Physiol Endocrinol Metab, May 1, 2009; 296(5): E1022 - E1028. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. S. Chee, K. Morl, D. Lindner, N. Merten, G. W. Zamponi, P. E. Light, A. G. Beck-Sickinger, and W. F. Colmers The Third Intracellular Loop Stabilizes the Inactive State of the Neuropeptide Y1 Receptor J. Biol. Chem., November 28, 2008; 283(48): 33337 - 33346. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hase, T. Yokomizo, T. Shimizu, and M. Nakamura Characterization of an Orphan G Protein-coupled Receptor, GPR20, That Constitutively Activates Gi Proteins J. Biol. Chem., May 9, 2008; 283(19): 12747 - 12755. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Bongers, K. M. Krueger, T. R. Miller, J. L. Baranowski, B. R. Estvander, D. G. Witte, M. I. Strakhova, P. van Meer, R. A. Bakker, M. D. Cowart, et al. An 80-Amino Acid Deletion in the Third Intracellular Loop of a Naturally Occurring Human Histamine H3 Isoform Confers Pharmacological Differences and Constitutive Activity J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 888 - 898. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Zhuang and H. Matsunami Synergism of Accessory Factors in Functional Expression of Mammalian Odorant Receptors J. Biol. Chem., May 18, 2007; 282(20): 15284 - 15293. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Makino, E. R. Prossnitz, M. Bunemann, J. M. Wang, W. Yao, and G. W. Schmid-Schonbein G protein-coupled receptors serve as mechanosensors for fluid shear stress in neutrophils Am J Physiol Cell Physiol, June 1, 2006; 290(6): C1633 - C1639. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. P. Fitzsimons, U. A. Gompels, D. Verzijl, H. F. Vischer, C. Mattick, R. Leurs, and M. J. Smit Chemokine-Directed Trafficking of Receptor Stimulus to Different G Proteins: Selective Inducible and Constitutive Signaling by Human Herpesvirus 6-Encoded Chemokine Receptor U51 Mol. Pharmacol., March 1, 2006; 69(3): 888 - 898. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-H. Feng, L. Zhou, R. Qiu, and R. Zeng Single Mutations at Asn295 and Leu305 in the Cytoplasmic Half of Transmembrane {alpha}-Helix Domain 7 of the AT1 Receptor Induce Promiscuous Agonist Specificity for Angiotensin II Fragments: A Pseudo-Constitutive Activity Mol. Pharmacol., August 1, 2005; 68(2): 347 - 355. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Perez and S. S. Karnik Multiple Signaling States of G-Protein-Coupled Receptors Pharmacol. Rev., June 1, 2005; 57(2): 147 - 161. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Lagane, S. Ballet, T. Planchenault, K. Balabanian, E. Le Poul, C. Blanpain, Y. Percherancier, I. Staropoli, G. Vassart, M. Oppermann, et al. Mutation of the DRY Motif Reveals Different Structural Requirements for the CC Chemokine Receptor 5-Mediated Signaling and Receptor Endocytosis Mol. Pharmacol., June 1, 2005; 67(6): 1966 - 1976. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. I. Boulware, J. P. Weick, B. R. Becklund, S. P. Kuo, R. D. Groth, and P. G. Mermelstein Estradiol Activates Group I and II Metabotropic Glutamate Receptor Signaling, Leading to Opposing Influences on cAMP Response Element-Binding Protein J. Neurosci., May 18, 2005; 25(20): 5066 - 5078. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Moresco and M. R. Koelle Activation of EGL-47, a G{alpha}o-Coupled Receptor, Inhibits Function of Hermaphrodite-Specific Motor Neurons to Regulate Caenorhabditis elegans Egg-Laying Behavior J. Neurosci., September 29, 2004; 24(39): 8522 - 8530. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. P. Fitzsimons, F. Monczor, N. Fernandez, C. Shayo, and C. Davio Mepyramine, a Histamine H1 Receptor Inverse Agonist, Binds Preferentially to a G Protein-coupled Form of the Receptor and Sequesters G Protein J. Biol. Chem., August 13, 2004; 279(33): 34431 - 34439. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Beinborn, Y. Ren, M. Blaker, C. Chen, and A. S. Kopin Ligand Function at Constitutively Active Receptor Mutants Is Affected by Two Distinct Yet Interacting Mechanisms Mol. Pharmacol., March 1, 2004; 65(3): 753 - 760. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kenakin Efficacy as a Vector: the Relative Prevalence and Paucity of Inverse Agonism Mol. Pharmacol., January 1, 2004; 65(1): 2 - 11. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Christopoulos and T. Kenakin G Protein-Coupled Receptor Allosterism and Complexing Pharmacol. Rev., June 1, 2002; 54(2): 323 - 374. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Ford, A. Essex, T. A. Spalding, E. S. Burstein, and J. Ellis Homologous Mutations Near the Junction of the Sixth Transmembrane Domain and the Third Extracellular Loop Lead to Constitutive Activity and Enhanced Agonist Affinity at all Muscarinic Receptor Subtypes J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 810 - 817. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. KENAKIN Inverse, protean, and ligand-selective agonism: matters of receptor conformation FASEB J, March 1, 2001; 15(3): 598 - 611. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Wade, K.-L. Lan, D. J. Moore, and R. R. Neubig Inverse Agonist Activity at the {alpha}2A-Adrenergic Receptor Mol. Pharmacol., March 1, 2001; 59(3): 532 - 542. [Abstract] [Full Text] |
||||
![]() |
S. Rees, D. P. Martin, S. V. Scott, S. H. Brown, N. Fraser, C. O'Shaughnessy, and I. J.M. Beresford Development of a Homogeneous MAP Kinase Reporter Gene Screen for the Identification of Agonists and Antagonists at the CXCR1 Chemokine Receptor J Biomol Screen, February 1, 2001; 6(1): 19 - 27. [Abstract] [PDF] |
||||
![]() |
S. Claeysen, M. Sebben, C. Bécamel, R. M. Eglen, R. D. Clark, J. Bockaert, and A. Dumuis Pharmacological Properties of 5-Hydroxytryptamine4 Receptor Antagonists on Constitutively Active Wild-Type and Mutated Receptors Mol. Pharmacol., July 1, 2000; 58(1): 136 - 144. [Abstract] [Full Text] |
||||
![]() |
C. Parnot, S. Bardin, S. Miserey-Lenkei, D. Guedin, P. Corvol, and E. Clauser Systematic identification of mutations that constitutively activate the angiotensin II type 1A receptor by screening a randomly mutated cDNA library with an original pharmacological bioassay PNAS, June 13, 2000; (2000) 110142297. [Abstract] [Full Text] |
||||
![]() |
C. Parnot, S. Bardin, S. Miserey-Lenkei, D. Guedin, P. Corvol, and E. Clauser Systematic identification of mutations that constitutively activate the angiotensin II type 1A receptor by screening a randomly mutated cDNA library with an original pharmacological bioassay PNAS, June 20, 2000; 97(13): 7615 - 7620. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||